PARP1 and neoplasm: However, compounds identified from other studies, such as olaparib50, a PARP1 inhibitor, were only moderately effective in our organoid models, indicating potential biological differences between tumor cell lines and patient-derived organoid models (Supplementary Fig. 6b).